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the biological activity of the Ras proteins, the key molecular path-
ways downstream of K-Ras involved in promoting lung tumorigenesis 
need to be identiﬁed in order to provide better targets for lung cancer 
therapy. We hypothesize that a crucial target of oncogenic K-Ras in the 
lung is nuclear factor kappa B (NFκB). NFκB is a dimeric transcription 
factor that promotes proliferation, mediates resistance to apoptosis, and 
is abnormally activated in a large variety of human malignancies. 
Methods: In order to analyze the role of NFκB downstream of K-Ras 
in the airway epithelium, a tetracycline-inducible system was used 
to stably and inducibly express either the wild type form of K-Ras 
(K-RasWT) or the oncogenic form (K-RasV12) in the lung adenocarci-
noma H1703 cell line. We also analyzed primary human bronchial cells 
that were either immortalized (AALEB) or immortalized and trans-
formed with K-RasV12 (AALEB-K-Ras). NFκB activity in these cells 
was analyzed by western blotting, eletrophoretic mobility shift assays, 
luciferase assays and expression of NFκB target genes by real-time 
PCR. 
Results: Expression of K-Ras-WT or K-RasV12 in H1703 cells after 
tetracycline induction was accompanied by both increased expression 
of NFκB target genes, and increased NFκB DNA binding activity. 
DNA binding was mediated primarily by p50 and p65 NFκB subunits. 
Although NFκB luciferase reporter activity was detectable prior to K-
Ras expression, expression of K-RasV12, but not K-Ras-WT, enhanced 
NFκB activity. Interestingly, K-RasV12 does not activate NFκB by the 
canonical NFκB activation pathway; in both H1703 and AALEB cells 
expressing K-RasV12, there was no increase in IkappaBalpha (IκBα) 
phosphorylation/degradation. Nonetheless, activation seems to be 
dependent on IkappaB kinase (IKK) activity for the following reasons: 
(1) When compared to AALEB cells, AALEB K-Ras cells displayed 
increased IKK phosphorylation levels; and (2) speciﬁc inhibition of 
IKKβ activity in H1703 cells by the novel pyridine derivative com-
pound 65-1942 (obtained under MTA agreement with Bayer) sup-
pressed NFκB activity. Finally, as no increase in p65 phosphorylation 
at S536 was observed in either cell type expressing K-RasV12, the 
mechanism of NFκB activation does not involve direct phosphorylation 
of p65 at S536 by IKK. 
Conclusions: We have determined a causal link between K-RasV12 
expression and NFκB activation in lung epithelial cells in vitro. NFκB 
in these cells is not activated either by the canonical pathway of IκBα 
phosphorylation/degradation or by p65 phosphorylation at S536. Al-
though the speciﬁc mechanism of activation is being investigated both 
in H1703 and in primary AALEB cells, we have shown that it depends 
on IKK. IKKβ inhibitors, therefore, represent a potentially promising 
new therapeutic direction in lung cancer. Studies are underway to con-
ﬁrm their efﬁcacy in a pre-clinical lung cancer mouse model.
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Background: Geﬁtinib, a selective tyrosine kinase inhibitor (TKI) of 
epidermal growth factor receptor (EGFR), may inhibit functions of 
ATP-binding cassette (ABC) transporters by competing against the ATP 
binding sites. The aim of this study is to investigate the combination 
effects of geﬁtinib plus four commomly used chemotherapeutic agents 
for the treatment of non-small cell lung cancer (NSCLC) in a geﬁtinib-
insensitive lung cancer cell line and its adriamycin-induced multi-drug 
resistant subclones. 
Methods: NCI-H23 was a lung adenocarcinoma cell line with wide 
type EGFR gene expression. Its high P-glycoprotein (Pgp) expression 
subclones H23 adr 0.1 and H23 adr 0.3 were developed by stepwise 
exposure to escalating concentrations of adriamycin. The expression 
levels of (Pgp), breast cancer resistant protein (BCRP), and mutidrug 
resistant protein-1 (MRP-1) were checked by RT-QPCR and immunob-
lot. The combination effects of geﬁtinib plus single chemotherapeutic 
agents including paclitaxel (Pac), docetaxel (Doc), vinorelbine (NVB) 
and gemcitabine (Gem) were evaluated by using the tetrazolium dye 
colormetric assay with application of the classical isobole methods in 
these cell lines. To evaluate the inhibition of ABC transporters-medi-
ated drugs efﬂux, Rhodamine 6G was used as the ﬂuorescence probe 
for evaluating the inhibitory effects of geﬁtinib (0-10 μM) on the ABC 
transporters. 
Results: We found that H23 Pgp subclones showed increased resis-
tance to three antitubulins, Pac, Doc and NVB, but not to Gem and ge-
ﬁtinib. Geﬁtinib could partially reverse Pgp related Pac, Doc and NVB 
resistance in a dose-dependent fashion, showing marked synergistic ef-
fects, while geﬁtinib showed an additive combination effect with Gem. 
There was no statistical difference in the values of combination index 
between geﬁtinib plus each antitubulins. Rhodamine 6G-efﬂux assay in 
the tested cell lines revealed that ﬂuorescence-efﬂux was inhibited with 
ﬂuorescence accumulation by geﬁtinib in a dose-dependent fashion. 
Conclusions: Our results showed that geﬁtinib could enhance cytotox-
icities of anti-tubulines in Pgp expressing NSCLC cells which showed 
wild type EGFR. Our results provide a rationale to test these combina-
tions as salvage treatment in NSCLC patients who failed prior antitubu-
lin treatment and also in patients whose tumors express high Pgp.
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Animal studies demonstrated that females are more susceptible than 
males to benzo[a]pyrene (BaP)-induced toxicities, including lung car-
cinogenesis. Elevation of cyclooxygenase-2 (COX-2) ex-pression has 
been shown to increase the risk of cancer development. BaP induces 
COX-2 expression, and an interaction between BaP and estrogen in 
relation to COX-2 expression is suspected. In the present study, 10 
mMBaP alone only slightly increased COX-2 mRNA expression and 
10 nM 17-beta estradiol (E2) alone slightly increased prostaglandin 
E2 (PGE2) secretion in human bronchial epithelial cells. However, 
co-treatment with BaP and E2 potentiated COX-2 mRNA expression 
and signiﬁcantly elevated PGE2 secretion. Utilizing speciﬁc inhibitors 
and reporter assays, we further investigated the potentiation mecha-
nisms of E2 on BaP-induced COX-2 expression. First, E2 activated 
estrogen receptor to increase PGE2 secretion, which directly increased 
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COX-2 expression. Second, E2 potentiated BaP-induced nuclear fac-
tor-kB (NF-kB) activation, which regulates COX-2 expression. Third, 
although the aryl hydrocarbon receptor (AhR) did not play a role in 
BaP-induced COX-2 expression, the potentiation effect of E2 itself 
was AhR dependent. We further demonstrated that BaP induced the 
production of genotoxic E2 metabolites (2- and 4- hydroxyestradiols) 
via AhR-up-regulated cytochromes P450 1A1 and 1B1. These metabo-
lites could directly activate NF-kB to further promote COX-2 mRNA 
expression in human lung epithelial cells. These ﬁndings were further 
supported by increased PGE2 secretion in rat lung slice cultures. Our 
ﬁndings that the BaP-VE2 interaction enhanced COX-2 expression and 
hydroxyestradiol accumulation in the media of cultivated lung cells and 
tissues provide the needed scientiﬁc basis for higher risk of BaP-associ-
ated lung cancer in females.
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Small cell lung carcinoma (SCLC) is a highly metastatic disease with 
a poor prognosis due to its resistance to current modes of therapy. 
SCLC appears to arise from neuroendocrine cells with the potential 
to differentiate into a variety of lung epithelial cell lineages. In order 
to investigate molecular events underlying the cell type transition in 
SCLC, we established a differentiation cell model by modiﬁcation of a 
SCLC cell line H526 with a differentiation inducing agent 5-bromode-
oxyuridine (BrdU). The BrdU treatment led to a dramatic conversion 
from a suspension cell line H526 to an adherent cell line variant H526B 
exhibiting an epithelioid phenotype. DNA ﬁngerprinting by random 
ampliﬁed polymorphic DNA (RAPD) method showed an identical 
DNA binding pattern between H526 and H526B, indicating that the 
H526B subpopulation arose from the original cell line H526 and the 
contamination from other cell types can be ruled out. The BrdU modi-
ﬁed cells H526B remarkably reduced the ability of colony formation 
in soft agar and suppressed the tumor growth rate in immune-deﬁcient 
nude mice. The phenotypic transition was consistent with upregula-
tion of several lung cancer differentiation markers such as surfactant 
protein C (SFTPC), thyroid transcription factor 1 (TTF-1), Connexin 
26 (Cx26), insulin-like growth factor binding protein-related protein 
1 (IGFBP-rP1), as well as homeobox genes like LAGY, PITX1 and 
HOXB2. Our data suggest that BrdU induced cell differentiation could 
be linked to the development of a less aggressively phenotype in small 
cell lung cancer. 
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Transforming growth factor-β (TGF-β) is an essential regulator of cel-
lular physiological processes including proliferation, differentiation and 
angiogenesis. 
TGF-β signaling is mediated through a heterotetrameric cell-surface 
receptor complex of type II receptor (TβII) and type I receptor (TβRI); 
type I receptor. Type I receptor has 2 subtypes known as activin recep-
tor-like kinase 5 (ALK5: known as TβI) and activin receptor-like 
kinase 1 (ALK1). TβII/ALK5 complex activates Smad2/3 pathway and 
TβRII/ALK1 complex activates Smad 1/5 pathway. These pathways 
have been known to be associated with cellular growth inhibition 
through induction of phosphorylated Smad2; whereas cellular prolifera-
tion through induction of phosphorylated Sma1/5 in cancer cells.
Retinoids have been shown to possess differentiation, antiproliferative 
and apoptosis-inducing properties in cancer cells. 
We have studied the effects of all-trans retinoic acid (ATRA) after 
treated with different levels of TGF-β1 in non-small cell lung cancer 
cell lines (NSCLCs). In addition, we examed whether ATRA effects in 
signal pathway of NSCLCs.
We analyzed expression of TGF-β receptor I and II (TGF-β I, TGF-β 
RII) by RT-PCR and treated with ATRA and a variety of concentrations 
of TGF-β1 for different durations in NSCLCs. In addition, the time-de-
pendent cytotoxic effects of ATRA alone, TGF-β1 alone and combina-
tion were studied by the MTT and cell counting assays. We carried out 
western blot analysis to evaluate whether combined treatment affects 
the expression of Smads or TGF-β RI (ALK5, ALK1). Finally, we car-
ried out migration assay to evaluate whether the combined treatment of 
ATRA and TGF-β1 affects the migration of NSCLCs.
The results showed that TGF-β1 alone increased cellular growth of 
NSCLCs, and the combined treatment of ATRA and TGF-β1 inhibited 
the growth of NSCLCs. The combined treatment of ATRA and TGF-
β1 reduced TGF-β1-induced phosphorylated Smad1/5/8. However, 
the total protein levels of ALK5 and ALK1 were not changed by the 
combined treatment of ATRA and TGF-β1. In addition, the combined 
treatment of ATRA and TGF-β1 reduced migration compared to the 
treatment with TGF-β1 in A549 and H1299 cell lines. 
Therefore, these ﬁndings suggest that treatment with ATRA reduced 
the growth and migration of NSCLCs by inhibition of TGF-β1-induced 
phosphorylated-Smad1/5/8 which caused growth progression and 
migration. ATRA may have a potential therapeutic role in the treatment 
of lung cancer patients with increased levels of TGF-β1.
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